Alpha Tau Medical Ltd (DRTS) Stock Analysis
Verdict: WATCH (do not buy)
Clinical momentum in Alpha DaRT trials drives re-rating potential, but zero commercial revenue and trial execution risks dominate long-term value.
Investment score: 45/100
Analysis as of
Is Alpha Tau Medical Ltd stock worth reviewing? AI model thesis
Alpha Tau Medical offers high-upside clinical exposure to innovative alpha-radiation oncology, but a $1.34B valuation for a pre-revenue asset limits near-term entry appeal.
7-factor investment score
- Valuation: 30/100 (weight 20%)
- Financial Health: 55/100 (weight 15%)
- Technical Momentum: 75/100 (weight 15%)
- Earnings Quality: 25/100 (weight 15%)
- Insider Sentiment: 20/100 (weight 10%)
- Analyst Consensus: 70/100 (weight 10%)
- Risk-Adjusted Return: 45/100 (weight 15%)
Alpha Tau Medical Ltd opportunities and risks
What speaks for DRTS
- Breakthrough clinical data in difficult-to-treat solid tumors
What speaks against DRTS
- Binary clinical trial and regulatory approval risk
Peers and competitors
| Ticker | P/E | P/S | EV/EBITDA | Gross margin | Net margin | FCF yield |
|---|---|---|---|---|---|---|
| DRTS | n/a | 0.0x | n/a | 0.0% | 0.0% | -2.4% |
| INMD | 11.4x | 2.2x | 5.1x | 76.5% | 20.7% | 10.7% |
| Peer median | 11.4x | 2.2x | 5.1x | 76.5% | 20.7% | 10.7% |
Frequently asked questions about Alpha Tau Medical Ltd (DRTS)
Is DRTS stock a good investment?
The cached TradeMates AI model rates Alpha Tau Medical Ltd as WATCH (do not buy) with an investment score of 45/100. Alpha Tau Medical offers high-upside clinical exposure to innovative alpha-radiation oncology, but a $1.34B valuation for a pre-revenue asset limits near-term entry appeal. This is algorithmic model output, not personal investment advice.
Is DRTS stock a buy?
The TradeMates model verdict for DRTS is WATCH (do not buy) with an investment score of 45/100. Treat this as a model signal to review, not a personal buy recommendation.